CR20190363A - Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usándolo - Google Patents

Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usándolo

Info

Publication number: CR20190363A
Authority: CR; Costa Rica
Prior art keywords: treat; cognitive disorders; prevent cognitive; agent; produce
Prior art date: 2017-02-27

Application number

CR20190363A

Other languages

English (en)

Inventor

Jeanne E Baker

Batteur Sophie Parmentier

Daniel Stephen Malashock

Naoko Namiki

Hiroshi Eguchi

Takashi Murakami

Carl Mieczkowski

Gopalan Raghunathan (Raghu)

Akira Tanokura

Angela Marie Jablonski

Original Assignee

Teijin Pharma Ltd

Merck Sharp & Dohme

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-02-27

Filing date

2018-02-27

Publication date

2019-11-05

2018-02-27 Application filed by Teijin Pharma Ltd, Merck Sharp & Dohme filed Critical Teijin Pharma Ltd

2019-11-05 Publication of CR20190363A publication Critical patent/CR20190363A/es

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CR20190363A 2017-02-27 2018-02-27 Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usándolo CR20190363A (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2017035594A JP2018139530A (ja)	2017-02-27	2017-02-27	認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
PCT/IB2018/000249 WO2018154390A1 (en)	2017-02-27	2018-02-27	Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same

Publications (1)

Publication Number	Publication Date
CR20190363A true CR20190363A (es)	2019-11-05

Family

ID=62025891

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CR20190363A CR20190363A (es)	2017-02-27	2018-02-27	Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usándolo

Country Status (26)

Country	Link
US (3)	US10556950B2 (es)
EP (1)	EP3585810B1 (es)
JP (4)	JP2018139530A (es)
KR (1)	KR102701634B1 (es)
CN (2)	CN110382528A (es)
AR (2)	AR110875A1 (es)
AU (1)	AU2018224390C1 (es)
BR (1)	BR112019016490A2 (es)
CA (1)	CA3052538A1 (es)
CL (3)	CL2019002296A1 (es)
CO (1)	CO2019008786A2 (es)
CR (1)	CR20190363A (es)
DO (1)	DOP2019000215A (es)
EA (1)	EA201991726A1 (es)
GE (2)	GEAP202215170A (es)
IL (1)	IL267945B2 (es)
JO (1)	JOP20180014A1 (es)
MA (1)	MA47608A (es)
MX (2)	MX2019009945A (es)
MY (1)	MY193821A (es)
NI (1)	NI201900086A (es)
PE (2)	PE20191614A1 (es)
PH (1)	PH12019501929A1 (es)
SG (2)	SG11201907548PA (es)
TW (2)	TW202506718A (es)
WO (2)	WO2018154392A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI777183B (zh) *	2012-05-31	2022-09-11	公立大學法人大阪市立大學	失智症治療劑或預防劑
JP2020508054A (ja)	2017-02-17	2020-03-19	デナリセラピューティクスインコーポレイテッドＤｅｎａｌｉＴｈｅｒａｐｅｕｔｉｃｓＩｎｃ．	抗タウ抗体及びその使用方法
JP2018139530A (ja) *	2017-02-27	2018-09-13	帝人ファーマ株式会社	認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
UA129617C2 (uk)	2017-10-16	2025-06-18	Еісаі Р Енд Д Менеджмент Ко., Лтд.	Антитіло до тау та його застосування
US20210355199A1 (en)	2018-06-28	2021-11-18	University Of Virginia Patent Foundation	Compositions and methods for detecting and regulating fibronectin-integrin interaction and signaling
US12365724B2 (en) *	2018-12-10	2025-07-22	New York University	Antibodies binding to phospho-tau comprising phosphorylated Ser396 and Ser404 and methods of detecting thereof
US20220381790A1 (en)	2019-02-11	2022-12-01	University Of Virginia Patent Foundation	Selection and blockade of fertilization competent male and female gametes
WO2020186247A1 (en)	2019-03-13	2020-09-17	University Of Virginia Patent Foundation	Compositions and methods for promoting islet viability and enhancing insulin secretion
JP7181438B2 (ja) *	2019-08-06	2022-11-30	アプリノイアセラピューティクスリミテッド	病理学的タウ種に結合する抗体及びその使用
IL296519A (en) *	2020-06-02	2022-11-01	Teijin Pharma Ltd	Anti-igf-1 receptor humanized antibody
US20230265175A1 (en) *	2020-06-25	2023-08-24	Merck Sharp & Dohme Llc	High affinity antibodies targeting tau phosphorylated at serine 413
US20250034559A1 (en)	2021-11-17	2025-01-30	Voyager Therapeutics, Inc.	Compositions and methods for the treatment of tau-related disorders
CN115322255B (zh) *	2022-04-25	2025-03-07	上海药明生物医药有限公司	一种优化的Fc变体及其应用
KR20250069606A (ko)	2022-09-15	2025-05-19	보이저 테라퓨틱스, 인크.	타우 결합 화합물
WO2025122634A1 (en)	2023-12-05	2025-06-12	Voyager Therapeutics, Inc.	Compositions and methods for the treatment of tau-related disorders
WO2025207501A1 (en) *	2024-03-26	2025-10-02	Merck Sharp & Dohme Llc	Crystals of anti-human tau monoclonal antibody
CN119080924B (zh) *	2024-07-04	2025-02-25	上海交通大学医学院附属第九人民医院	一种单克隆免疫球蛋白及其用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS587390B2 (ja)	1975-03-11	1983-02-09	ツキシマキカイカブシキガイシヤ	ア−クヨウセツホウホウ
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5859205A (en)	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
EP0940468A1 (en)	1991-06-14	1999-09-08	Genentech, Inc.	Humanized antibody variable domain
WO1994004679A1 (en)	1991-06-14	1994-03-03	Genentech, Inc.	Method for making humanized antibodies
JP3587390B2 (ja)	1994-03-17	2004-11-10	タカラバイオ株式会社	リン酸化アミノ酸誘導体及びリン酸化ペプチド合成方法
JP4754352B2 (ja)	2003-08-29	2011-08-24	株式会社リバース・プロテオミクス研究所	タンパク質の固定化方法
JP2007512846A (ja)	2003-12-04	2007-05-24	ゼンコー・インコーポレイテッド	増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物
UA107571C2 (xx)	2009-04-03	2015-01-26		Фармацевтична композиція
US8609097B2 (en)	2009-06-10	2013-12-17	Hoffmann-La Roche Inc.	Use of an anti-Tau pS422 antibody for the treatment of brain diseases
EP2625198B1 (en)	2010-10-07	2015-07-22	AC Immune S.A.	Antibodies recognising phospho-tau
US8940272B2 (en) *	2010-10-11	2015-01-27	University Of Zurich	Human anti-tau antibodies
DK2794654T3 (da)	2011-12-20	2019-08-05	Janssen Biotech Inc	Anti-phf-tau-antistoffer og deres anvendelser
TWI777183B (zh) *	2012-05-31	2022-09-11	公立大學法人大阪市立大學	失智症治療劑或預防劑
SI2885010T1 (sl) *	2012-08-16	2020-07-31	Ipierian, Inc.	Metode zdravljenja tauopatije
BR112015014751A8 (pt)	2012-12-21	2018-01-16	Biogen Int Neuroscience Gmbh	anti-corpos anti-tau humanos e fragmento de ligação a tau dos mesmo, seu uso na preparação de um medicamento, bem como polipeptídeos codificando os mesmos.
EA039554B1 (ru)	2013-06-10	2022-02-09	АйПИЕРИАН, ИНК.	Способ снижения уровней a40 и/или a42 в нервной клетке и/или во внеклеточной жидкости
AU2014368696A1 (en)	2013-12-20	2016-06-02	F. Hoffmann-La Roche Ag	Humanized anti-Tau(pS422) antibodies and methods of use
AR100978A1 (es) *	2014-06-26	2016-11-16	Hoffmann La Roche	LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
TWI664190B (zh) *	2014-06-27	2019-07-01	美商Ｃ２Ｎ醫療診斷有限責任公司	人類化抗－ｔａｕ抗體
RU2017119185A (ru)	2014-11-05	2018-12-05	Дженентек, Инк.	Антитела против fgfr2/3 и способы их применения
WO2016112078A2 (en)	2015-01-08	2016-07-14	Janssen Biotech, Inc.	Anti-phf-tau antibodies and their uses
TN2017000543A1 (en)	2015-07-06	2019-04-12	Ucb Biopharma Sprl	Tau-binding antibodies
MA41670A1 (fr)	2015-07-06	2018-05-31	Ucb Biopharma Sprl	Anticorps se liant a tau
JO3711B1 (ar)	2015-07-13	2021-01-31	H Lundbeck As	أجسام مضادة محددة لبروتين تاو وطرق استعمالها
JP2018139530A (ja)	2017-02-27	2018-09-13	帝人ファーマ株式会社	認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤

2017
- 2017-02-27 JP JP2017035594A patent/JP2018139530A/ja active Pending
- 2017-02-27 JO JOP/2018/0014A patent/JOP20180014A1/ar unknown
2018
- 2018-02-25 WO PCT/IB2018/000267 patent/WO2018154392A1/en not_active Ceased
- 2018-02-26 TW TW113125487A patent/TW202506718A/zh unknown
- 2018-02-26 TW TW107106444A patent/TWI848904B/zh active
- 2018-02-27 PE PE2019001541A patent/PE20191614A1/es unknown
- 2018-02-27 SG SG11201907548PA patent/SG11201907548PA/en unknown
- 2018-02-27 BR BR112019016490A patent/BR112019016490A2/pt unknown
- 2018-02-27 US US15/906,773 patent/US10556950B2/en active Active
- 2018-02-27 CN CN201880008302.XA patent/CN110382528A/zh active Pending
- 2018-02-27 MX MX2019009945A patent/MX2019009945A/es unknown
- 2018-02-27 PE PE2024001024A patent/PE20241514A1/es unknown
- 2018-02-27 WO PCT/IB2018/000249 patent/WO2018154390A1/en not_active Ceased
- 2018-02-27 EA EA201991726A patent/EA201991726A1/ru unknown
- 2018-02-27 SG SG10201913419TA patent/SG10201913419TA/en unknown
- 2018-02-27 EP EP18718907.1A patent/EP3585810B1/en active Active
- 2018-02-27 JP JP2019545918A patent/JP7165996B2/ja active Active
- 2018-02-27 KR KR1020197024146A patent/KR102701634B1/ko active Active
- 2018-02-27 AR ARP180100454A patent/AR110875A1/es unknown
- 2018-02-27 IL IL267945A patent/IL267945B2/en unknown
- 2018-02-27 CR CR20190363A patent/CR20190363A/es unknown
- 2018-02-27 MA MA047608A patent/MA47608A/fr unknown
- 2018-02-27 MY MYPI2019004787A patent/MY193821A/en unknown
- 2018-02-27 CN CN202010117151.0A patent/CN111320695B/zh active Active
- 2018-02-27 GE GEAP202215170A patent/GEAP202215170A/en unknown
- 2018-02-27 CA CA3052538A patent/CA3052538A1/en active Pending
- 2018-02-27 GE GEAP201815170A patent/GEP20227392B/en unknown
- 2018-02-27 AU AU2018224390A patent/AU2018224390C1/en active Active
2019
- 2019-08-09 NI NI201900086A patent/NI201900086A/es unknown
- 2019-08-13 CL CL2019002296A patent/CL2019002296A1/es unknown
- 2019-08-13 CO CONC2019/0008786A patent/CO2019008786A2/es unknown
- 2019-08-15 DO DO2019000215A patent/DOP2019000215A/es unknown
- 2019-08-20 MX MX2023013246A patent/MX2023013246A/es unknown
- 2019-08-20 PH PH12019501929A patent/PH12019501929A1/en unknown
- 2019-08-22 AR ARP190102386A patent/AR117952A2/es unknown
2020
- 2020-01-17 US US16/746,725 patent/US10894829B2/en active Active
- 2020-12-15 US US17/122,325 patent/US11739143B2/en active Active
2021
- 2021-09-13 CL CL2021002389A patent/CL2021002389A1/es unknown
2022
- 2022-10-18 JP JP2022166859A patent/JP2023002670A/ja active Pending
2024
- 2024-02-02 CL CL2024000339A patent/CL2024000339A1/es unknown
- 2024-08-28 JP JP2024146101A patent/JP2024170459A/ja active Pending

Also Published As

Publication number	Publication date
US11739143B2 (en)	2023-08-29
NI201900086A (es)	2019-10-08
IL267945B2 (en)	2025-10-01
CN111320695B (zh)	2021-09-03
AU2018224390C1 (en)	2025-04-17
CA3052538A1 (en)	2018-08-30
GEP20227392B (en)	2022-06-27
JP2023002670A (ja)	2023-01-10
JP2018139530A (ja)	2018-09-13
BR112019016490A2 (pt)	2020-04-07
AR110875A1 (es)	2019-05-08
AU2018224390B2 (en)	2024-10-31
US20200223916A1 (en)	2020-07-16
PE20241514A1 (es)	2024-07-19
KR102701634B1 (ko)	2024-08-30
TW202506718A (zh)	2025-02-16
SG11201907548PA (en)	2019-09-27
MX2023013246A (es)	2023-11-21
MX2019009945A (es)	2019-11-05
GEAP202215170A (en)	2022-02-10
TW201843179A (zh)	2018-12-16
TWI848904B (zh)	2024-07-21
JP2020508666A (ja)	2020-03-26
CL2024000339A1 (es)	2024-08-16
MY193821A (en)	2022-10-27
US20210380677A1 (en)	2021-12-09
CL2019002296A1 (es)	2019-11-29
EA201991726A1 (ru)	2020-01-30
JP2024170459A (ja)	2024-12-10
EP3585810B1 (en)	2025-11-26
JOP20180014A1 (ar)	2019-01-30
MA47608A (fr)	2020-01-01
US10894829B2 (en)	2021-01-19
JP7165996B2 (ja)	2022-11-07
CO2019008786A2 (es)	2019-08-20
AU2018224390A1 (en)	2019-07-11
WO2018154392A1 (en)	2018-08-30
PE20191614A1 (es)	2019-11-05
CN110382528A (zh)	2019-10-25
CN111320695A (zh)	2020-06-23
CL2021002389A1 (es)	2022-04-22
DOP2019000215A (es)	2019-09-30
EP3585810A1 (en)	2020-01-01
IL267945B1 (en)	2025-06-01
US10556950B2 (en)	2020-02-11
IL267945A (en)	2019-09-26
SG10201913419TA (en)	2020-03-30
PH12019501929A1 (en)	2020-06-29
AR117952A2 (es)	2021-09-08
US20180346564A1 (en)	2018-12-06
WO2018154390A1 (en)	2018-08-30
KR20190122674A (ko)	2019-10-30

Publication	Publication Date	Title
CL2024000339A1 (es)	2024-08-16	Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo.
CL2019001411A1 (es)	2019-08-02	Métodos para inhibición de la fibrosis en un sujeto en necesidad de ellos. (divisional solicitud 201801817)
CL2019003114A1 (es)	2020-06-19	Anticuerpos anti–tau y métodos de uso (divisional solicitud 201703063)
CO2021004560A2 (es)	2021-04-30	Anticuerpos estabilizadores de trem2
JOP20200132A1 (ar)	2022-10-30	صيغة مجففة بالتبريد من جسم مضاد أحادي النسيلة ضد ترانس ثيرتين
SA520420801B1 (ar)	2023-12-07	أil جسام مضادة لـ -11
CL2018002694A1 (es)	2018-11-23	Moleculas de anticuerpos que se unen a lag-3 y usos de las mismas (divisional solicitud 201602112)
MX2022010229A (es)	2022-09-19	Composicion para profilaxis o tratamiento de enfermedades relacionadas con interleucina 8 (il-8).
BR112019002331A2 (pt)	2019-06-18	anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos
EA201991862A1 (ru)	2020-02-04	Композиции и способы, предназначенные для лечения гемоглобинопатий
MX2022011002A (es)	2022-10-07	Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos.
CR20190271A (es)	2019-09-03	Anticuerpos antitau y métodos de uso
JOP20180117B1 (ar)	2022-03-14	أجسام مضادة انتقائية لـ tau فائق المعالجة بفوسفوريلات وطرق لاستخدامها
JO3692B1 (ar)	2020-08-27	عوامل، استخدامات وطرق لعلاج مرض تنكسي عصبي
EA201791527A1 (ru)	2017-12-29	Биспецифические антитела против плазменного калликреина и фактора xii
JOP20220119A1 (ar)	2023-01-30	أجسام مضادة trem2 واستخداماتها
MX2019011423A (es)	2019-11-01	Metodos de tratamiento de enfermedades neurodegenerativas.
EA201990400A1 (ru)	2019-07-31	Соединения и композиции и их применение
EA201892225A1 (ru)	2019-09-30	АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
EA202090944A1 (ru)	2020-07-16	Анти-cd3-антитело и фармацевтическая композиция для лечения онкологических заболеваний, содержащая его
UY36262A (es)	2016-04-01	Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso
EA201990253A1 (ru)	2019-06-28	Гуманизированные антитела против s100a9 и их применение
UY37914A (es)	2019-04-30	Anticuerpo monoclonal contr il-5r
MX391162B (es)	2025-03-21	Anticuerpos altamente potentes que se unen a receptor de muerte 4 y receptor de muerte 5
EA202090330A1 (ru)	2020-06-02	Композиции и способы лечения расстройств, связанных со стрессом